[go: up one dir, main page]

MX383353B - Uso de antagonistas de receptores de glucocorticoides en combinacion con glucocorticoides para tratar la insuficiencia adrenal. - Google Patents

Uso de antagonistas de receptores de glucocorticoides en combinacion con glucocorticoides para tratar la insuficiencia adrenal.

Info

Publication number
MX383353B
MX383353B MX2017011885A MX2017011885A MX383353B MX 383353 B MX383353 B MX 383353B MX 2017011885 A MX2017011885 A MX 2017011885A MX 2017011885 A MX2017011885 A MX 2017011885A MX 383353 B MX383353 B MX 383353B
Authority
MX
Mexico
Prior art keywords
adrenal insufficiency
glucocorticoid receptor
glucocorticoid
patient
glucocorticoids
Prior art date
Application number
MX2017011885A
Other languages
English (en)
Other versions
MX2017011885A (es
Inventor
Andreas G Moraitis
Joseph K Belanoff
Pejman Cohan
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of MX2017011885A publication Critical patent/MX2017011885A/es
Publication of MX383353B publication Critical patent/MX383353B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención provee un método para tratar la insuficiencia adrenal secundaria mediante la administración conjunta de cantidades efectivas de un glucocorticoide y un antagonista de receptor de glucocorticoide al paciente que necesita del mismo. En algunas realizaciones, el método incluye la condición de que el paciente no necesite de otro modo el tratamiento con un glucocorticoide y un antagonista de receptor de glucocorticoide. El método de tratamiento puede aumentar el nivel de cortisol de la mañana o basal del paciente hasta un nivel de por lo menos 12 µg/dL o un nivel control normal y a su vez, acelerar significativamente la recuperación del eje HPA. El método provisto en la presente puede mejorar los resultados de la salud y las complicaciones que amenazan la vida asociadas con la insuficiencia adrenal secundaria.
MX2017011885A 2015-03-30 2016-03-30 Uso de antagonistas de receptores de glucocorticoides en combinacion con glucocorticoides para tratar la insuficiencia adrenal. MX383353B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562140317P 2015-03-30 2015-03-30
PCT/US2016/024981 WO2016160969A1 (en) 2015-03-30 2016-03-30 Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency

Publications (2)

Publication Number Publication Date
MX2017011885A MX2017011885A (es) 2018-02-19
MX383353B true MX383353B (es) 2025-03-13

Family

ID=57006281

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011885A MX383353B (es) 2015-03-30 2016-03-30 Uso de antagonistas de receptores de glucocorticoides en combinacion con glucocorticoides para tratar la insuficiencia adrenal.

Country Status (13)

Country Link
US (4) US10610534B2 (es)
EP (1) EP3277281B1 (es)
JP (3) JP6754533B2 (es)
KR (1) KR102495223B1 (es)
CN (1) CN107530339B (es)
AU (1) AU2016243625B2 (es)
CA (1) CA2978960C (es)
ES (1) ES2906778T3 (es)
IL (1) IL254787B (es)
MX (1) MX383353B (es)
SG (1) SG11201707525TA (es)
WO (1) WO2016160969A1 (es)
ZA (1) ZA201706101B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016243625B2 (en) 2015-03-30 2020-09-10 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
WO2017041006A1 (en) 2015-09-03 2017-03-09 Questek Innovations Llc Aluminum alloys
EP3600282B1 (en) 2017-03-31 2025-09-10 Corcept Therapeutics Incorporated Glucocorticoid receptor modulators to treat cervical cancer
GB201816621D0 (en) * 2018-10-12 2018-11-28 Univ Leuven Kath Prevention or treatment of adrenal insuffiency in critically ill patients
EP4076470B1 (en) * 2019-12-21 2025-12-03 Corcept Therapeutics Incorporated Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome
JP2023065127A (ja) 2021-10-27 2023-05-12 キヤノン株式会社 インク及び画像の読み取り方法
IL320512A (en) 2022-10-28 2025-06-01 Corcept Therapeutics Inc Amyotrophic lateral sclerosis treatments using desocorilant

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296206A (en) 1980-04-30 1981-10-20 United States Of America Irreversible anti-glucocorticoids
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
US4978657A (en) 1981-01-09 1990-12-18 Roussel Uclaf Novel 11β-substituted-19-nor-steroids
FR2528434B1 (fr) 1982-06-11 1985-07-19 Roussel Uclaf Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
FR2639045B2 (fr) 1982-03-01 1994-07-29 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto-delta-4,9-19-nor steroides et leur application comme medicaments
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
DE3438994A1 (de) 1984-10-22 1986-04-24 Schering AG, Berlin und Bergkamen, 1000 Berlin Antigestagene, glukokortikoide und prostaglandine zur geburtseinleitung oder fuer den schwangerschaftsabbruch
FR2576025B1 (fr) 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
AU580843B2 (en) 1985-02-07 1989-02-02 Schering Aktiengesellschaft 11``-phenyl-gonanes, their manufacture and pharmaceutical preparations containing them
DE3506785A1 (de) 1985-02-22 1986-08-28 Schering AG, Berlin und Bergkamen, 1000 Berlin 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
US5506354A (en) 1985-09-12 1996-04-09 The Upjohn Company Imidazolylpiperazinyl steroids
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
EP0254341B1 (en) 1986-07-23 1990-01-03 Akzo N.V. Novel 18-phenyloestrane derivatives
DE3625315A1 (de) 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
US4774236A (en) 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
US4861763A (en) 1986-09-17 1989-08-29 Research Triangle Institute 17 α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and their progestational use
US4921638A (en) 1986-11-05 1990-05-01 The Upjohn Company 17β-cyano-9α,17α-dihydroxyandrost-4-en-3-one
DE3708942A1 (de) 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3723788A1 (de) 1987-07-16 1989-01-26 Schering Ag 11(beta)-phenyl-4,9,15-estratriene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2618783B1 (fr) 1987-07-30 1991-02-01 Roussel Uclaf Nouveaux 17-aryle steroides, leurs procedes et des intermediaires de preparation comme medicaments et les compositions pharmaceutiques les renfermant
JP2785023B2 (ja) 1987-12-30 1998-08-13 ルセル―ユクラフ １７α位置を置換された１７β―ＯＨ―１９―ノルステロイドの新誘導体、その製造方法、その薬剤としての使用及びそれを含有する製薬組成物
DE3820948A1 (de) 1988-06-16 1989-12-21 Schering Ag 10ss, 11ss-ueberbrueckte steroide
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5348729A (en) 1988-11-30 1994-09-20 The United States Of America As Represented By The Department Of Health And Human Services Evaluative means for detecting inflammatory reactivity
DD289541A5 (de) 1989-08-04 1991-05-02 ��@�K@�������������@�K@��������������@��������k�� Verfahren zur herstellung von 11beta-aryl-16 alpha, 17 alph-cyclohexanoestra-4,9-dienen
US5276023A (en) 1989-08-08 1994-01-04 Roussel Uclaf 19-nor-steroid esters
FR2651233B1 (fr) 1989-08-23 1991-12-13 Roussel Uclaf Nouveaux acides omega-phenylamino alcanouiques substitues sur le noyau aromatique par un radical derive de 19-norsterouides, leur procede de preparation, leur application a titre de medicaments et les compositions les renfermant.
US5173405A (en) 1990-01-23 1992-12-22 The United States Of America As Represented By The Department Of Health And Human Services Use of arsenite to reversibly block steroid binding to glucocorticoid receptors in the presence of other steroid receptors
US5616458A (en) 1990-03-14 1997-04-01 Board Of Regents, University Of Tx System Tripterygium wilfordii hook F extracts and components, and uses thereof
DE4042004A1 (de) 1990-12-22 1992-06-25 Schering Ag 14(beta)-h-, 14- u. 15-en-11(beta)-aryl-4-estrene
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
ZA953976B (en) 1994-05-19 1996-01-19 Akzo Nobel Nv 11,21-bisphenyl-19-norpregnane derivatives
US6051573A (en) 1994-06-28 2000-04-18 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with non-steroidal glucocorticoid antagonists
US5693647A (en) 1994-12-22 1997-12-02 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
PT800519E (pt) 1994-12-22 2004-03-31 Ligand Pharm Inc Compostos moduladores de receptores de esteroides e metodos
IL118974A (en) 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
WO1998027986A1 (en) 1996-12-24 1998-07-02 Zymogenetics, Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
EP0903146A1 (en) 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid
DE10038639A1 (de) 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
IL146057A (en) 2000-10-27 2007-09-20 Pfizer Prod Inc A process for the preparation of modulators of a non-steroidal glucocorticoid receptor
GB0119848D0 (en) 2001-08-15 2001-10-10 Univ Sheffield Delayed and sustained drug release
JP2005513024A (ja) 2001-11-23 2005-05-12 アクゾ・ノベル・エヌ・ベー グルココルチコイド受容体アンタゴニストを用いる大うつ病性障害の治療
CA2512987C (en) * 2003-01-21 2011-06-14 Merck & Co., Inc. 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators
WO2004067529A1 (en) * 2003-01-22 2004-08-12 Eli Lilly And Company Indole-derivative modulators of steroid hormone nuclear receptors
CN101027301B (zh) 2004-03-09 2011-06-29 科塞普特治疗公司 稠环氮杂十氢化萘糖皮质激素受体调节剂
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
WO2009050136A2 (en) * 2007-10-17 2009-04-23 Laboratoire Hra Pharma Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
AU2010247766B2 (en) 2009-05-12 2015-05-21 Corcept Therapeutics, Inc. Solid forms and process for preparing
WO2012094618A1 (en) * 2011-01-07 2012-07-12 Corcept Therapeutics, Inc. Combination steroid and glucocorticoid receptor antagonist therapy
AU2012231265B2 (en) 2011-03-18 2016-07-07 Corcept Therapeutics, Inc. Pyrimidine cyclohexyl glucocorticoid receptor modulators
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
ES2665338T3 (es) * 2012-05-25 2018-04-25 Corcept Therapeutics, Inc. Moduladores del receptor de glucocorticoides de azadecalina condensada con heteroaril-cetona
US20140170768A1 (en) * 2012-12-14 2014-06-19 Joel R. L. Ehrenkranz Method for monitoring and assessing pituitary function
EP4219494A1 (en) 2013-11-25 2023-08-02 Corcept Therapeutics Incorporated Octahydro fused azadecalin glucocorticoid receptor modulators
AU2016243625B2 (en) 2015-03-30 2020-09-10 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency

Also Published As

Publication number Publication date
KR102495223B1 (ko) 2023-02-01
ES2906778T3 (es) 2022-04-20
US11202784B2 (en) 2021-12-21
HK1248126A1 (zh) 2018-10-12
AU2016243625A1 (en) 2017-09-28
MX2017011885A (es) 2018-02-19
EP3277281A4 (en) 2018-12-05
IL254787A0 (en) 2017-12-31
CN107530339A (zh) 2018-01-02
JP6754533B2 (ja) 2020-09-16
CN107530339B (zh) 2021-03-16
JP2020073588A (ja) 2020-05-14
US11890289B2 (en) 2024-02-06
US20180078565A1 (en) 2018-03-22
ZA201706101B (en) 2020-03-25
JP2018510174A (ja) 2018-04-12
EP3277281A1 (en) 2018-02-07
JP2021175756A (ja) 2021-11-04
CA2978960C (en) 2023-05-02
WO2016160969A1 (en) 2016-10-06
US10610534B2 (en) 2020-04-07
US20220062297A1 (en) 2022-03-03
US20240156835A1 (en) 2024-05-16
SG11201707525TA (en) 2017-10-30
IL254787B (en) 2020-05-31
US20200206243A1 (en) 2020-07-02
AU2016243625B2 (en) 2020-09-10
EP3277281B1 (en) 2022-01-05
KR20170131665A (ko) 2017-11-29
CA2978960A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
MX383353B (es) Uso de antagonistas de receptores de glucocorticoides en combinacion con glucocorticoides para tratar la insuficiencia adrenal.
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
MX2020011562A (es) Agonistas del receptor de la hormona tiroidea y usos de los mismos.
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
IL261548B (en) 7α,β11-dihydroxy-6α-ethyl-5β-cholan-24-oic acid and its use for the treatment of paranoid x receptor activated conditions
PH12017501934A1 (en) Methods for treating or preventing migraine headache
PH12016502064A1 (en) Human antibodies to middle east respiratory syndrome-coronavirus spike protein
MX2018004947A (es) Metodos para el tratamiento de sindrome de angelman y de los trastornos relacionados.
MX2016014753A (es) Tratamiento de cancer de pulmon con el uso de una combinacion de un anticuerpo de muerte anti-programada 1 (anti-pd-1) y otro agente anti-cancerigeno.
TN2016000057A1 (en) Methods of treating sporadic inclusion body myositis
MX389759B (es) ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTOEGENESIS IMPERFECTA (OI).
MX2016014013A (es) Composiciones y metodos para modular la expresion del receptor de la hormona del crecimiento.
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
BR112021014699A2 (pt) Métodos de tratamento de mieloma múltiplo
NZ754676A (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
MX2017004943A (es) Tratamiento de la enfermedad del hígado graso usando antagonistas de receptores de glucocorticoides y de minerarlocorticoides.
BR112014014824A2 (pt) anticorpos antagonistas do receptor do hormônio de crescimento humano e métodos de uso dos mesmos
EP2661175A4 (en) COMBINATION STEROID AND GLUCOCORTICOID RECEPTORANT AGONIST THERAPY
PH12021550671A1 (en) Prodrugs of cgrp antagonists
PH12019502574A1 (en) Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
IL278906A (en) Compositions and methods for treating diseases or disorders related to steroid hormones
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
MA40536A (fr) Anticorps anti-alpha v bêta 5 humanisés et leurs utilisations
MX2016006657A (es) Antagonistas de gastrina (por ejemplo, yf476, netazepido) para el tratamiento y prevencion de osteoporosis.